Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement


A Phase 3, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, Safety, and Pharmacokinetics of 4975 in Patients Undergoing Primary Unilateral Total Knee Arthroplasty




Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement

Study Status: Completed


Condition Intervention Phase
Total Knee Arthroplasty (Replacement) Drug: 4975, 15 and 5 mg
Drug: Placebo Comparator
Drug: 4975 - 5 mg
Phase 3

Verified by Anesiva, Inc. May, 2009

Sponsored by: Anesiva, Inc.
Information provided by: Anesiva, Inc. identifier: NCT00681356

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care

Cleveland Clinic
Cleveland, Ohio 44195
United States

Shaun Comfort, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site